Menu
Recruiting NCT07344948

Single and Multiple Ascending Doses of NTX-253 in Healthy Participants and Participants With Stable Schizophrenia

Early Phase I Interventional Healthy Participants Schizophrenia Diagnosis

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: NTX-253, Placebo.
Who it may be relevant to
Registry conditions: Healthy Participants, Schizophrenia Diagnosis. Basic parameters: 18 years — 55 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

A First in Human, Phase 1/1b Study of Single and Multiple Ascending Dosing Administration of NTX110253 in Healthy Participants and Participants With Stable Schizophrenia

Overview

This study will assess the safety, tolerability, and pharmacokinetics of NTX-253 following oral administration in both healthy adult participants as well as adult participants with stable schizophrenia.

Detailed description

This study will assess the safety, tolerability, and pharmacokinetics of NTX-253 following oral administration in both healthy adult participants as well as adult participants with stable schizophrenia. NTX-253 is an investigational drug being developed for the treatment of schizophrenia. The study will consist of a single ascending dose (SAD - Part 1a) phase which will include a food effect cohort, and a cerebrospinal fluid (CSF - Part 1b) cohort in healthy volunteers. Participants will receive a single dose of either oral NTX-253 or placebo. The multiple ascending dose (MAD - Part 2) phase will follow. In Part 2, participants will be dosed for 10 consecutive days with either NTX-253 or placebo. Each phase will include sequential escalating doses in healthy volunteers. Two cohorts in the MAD phase will include stable schizophrenic adult participants who have had antipsychotic medication withdrawn for up to 8 days prior to dosing with NTX-253.

Interventions

  • Drug NTX-253
    Oral Capsule
  • Drug Placebo
    Oral capsule

Primary outcome measures

  • Number of reported Adverse Events [Time frame: From baseline until Day 8 after a single dose, Day 17 (healthy volunteers) or Day 35 (participants with stable schizophrenia).]
  • Number of Adverse Events of Special Interest (AESI) [Time frame: From baseline until Day 8 after a single dose, Day 17 (healthy volunteers) or Day 35 (participants with stable schizophrenia).]
  • Number of dose limiting treatment emergent adverse events (TEAE) [Time frame: From baseline until Day 8 after a single dose, Day 17 (healthy volunteers) or Day 35 (participants with stable schizophrenia).]
  • Vital Signs: Change in blood pressure [Time frame: From baseline until Day 8 after a single dose, Day 17 (healthy volunteers) or Day 35 (participants with stable schizophrenia).]
  • Vital Signs: Change in temperature [Time frame: From baseline until Day 8 after a single dose, Day 17 (healthy volunteers) or Day 35 (participants with stable schizophrenia).]
  • Vital Signs: Change in respiratory rate [Time frame: From baseline until Day 8 after a single dose, Day 17 (healthy volunteers) or Day 35 (participants with stable schizophrenia).]
  • Vital Signs: Change in heart rate [Time frame: From baseline until Day 8 after a single dose, Day 17 (healthy volunteers) or Day 35 (participants with stable schizophrenia).]
  • Change in physical examination [Time frame: From baseline until Day 8 after a single dose, Day 17 (healthy volunteers) or Day 35 (participants with stable schizophrenia).]
  • Clinical Laboratory Tests [Time frame: From baseline until Day 8 after a single dose, Day 17 (healthy volunteers) or Day 35 (participants with stable schizophrenia).]
Secondary outcome measures (9)
  • Maximum observed plasma concentration (Cmax) [Pharmacokinetics] [Time frame: From baseline until up to 168 hours after a single dose, or until up to 168 hours after the last dose in the multiple dose cohorts.]
  • Time of Cmax (tmax) [Pharmacokinetics] [Time frame: From baseline until up to 168 hours after a single dose, or until up to 168 hours after the last dose in the multiple dose cohorts.]
  • Apparent terminal half-life (t1/2) [Time frame: From baseline until up to 168 hours after a single dose, or until up to 168 hours after the last dose in the multiple dose cohorts.]
  • Amount of unchanged drug excreted in urine (Ae) [urinary excretion) [Time frame: From baseline until 72 hours after a single dose, or until the last dosing on Day 10 in the multiple dose cohort.]
  • Percent of dose excreted as unchanged drug in urine (Ae%) [urinary excretion] [Time frame: From baseline until 72 hours after a single dose, or until the last dosing on Day 10 in the multiple dose cohort.]
  • Renal clearance (Clr) [urinary excretion] [Time frame: From baseline until 72 hours after a single dose, or until the last dosing on Day 10 in the multiple dose cohort.]
  • Maximum observed CSF concentration (Cmax, CSF) [Pharmacokinetics] [Time frame: From baseline until 12 hours after a single dose.]
  • Time corresponding to Cmax (Tmax, CSF) [Pharmacokinetics] [Time frame: From baseline until 12 hours after a single dose.]
  • QT/QTc potential interval prolongation and plasma concentration [Time frame: From baseline until 72 hours post-dose in the single dose cohorts, then from baseline until Day 13 in the multiple dose cohorts.]

Eligibility criteria

Primary Inclusion Criteria:

  • Male or non-pregnant, non-lactating female participants, ages 18-55 who are not of childbearing potential, with a truly abstinent lifestyle, or agrees to use medically acceptable forms of birth control
  • Part 1 a/b, Part 2 Cohort 7 only: Body mass index (BMI) within the range ≥18.0 to ≤30.0 kg/m2
  • Participants in the food effect cohort must be willing to eat a single high fat breakfast
  • (Part 2 only): Stable schizophrenia participants (schizophrenia cohorts only)
  • Body mass index (BMI) within the range ≥17.5 to ≤36.0 kg/m2
  • Positive and Negative Syndrome Scale (PANSS) total score <80 at screening

Primary Exclusion Criteria:

  • (Part 1a/b, Part 2 Healthy): History of or current clinically significant medical or mental illness
  • Cancer diagnosis/treatment in the past 7 years
  • Acute or chronic gastrointestinal conditions that would interfere with drug tolerance or absorption
  • Any clinically significant, abnormal 12 lead ECG
  • Part 2: Any primary DSM-5TR disorder other than schizophrenia
  • Participants with schizophrenia who are considered resistant/refractory to antipsychotic treatment by history; history of clozapine use.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Double blind
Primary purpose
Treatment

Study locations

United States · 1 center
  • Collaborative Neuroscience Research, LLC - CenExel — Los Alamitos

Identifiers

NCT: NCT07344948 · NTX-0253-101

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗